HomeLatest ThreadsGreatest ThreadsForums & GroupsMy SubscriptionsMy Posts
DU Home » Latest Threads » slipslidingaway » Journal
Page: 1

slipslidingaway

Profile Information

Member since: Tue Nov 30, 2004, 07:08 PM
Number of posts: 21,210

Journal Archives

As Announced Yesterday By Vice President Joe Biden, LLS to Lead First-Ever Blood Cancer Master Trial

http://www.lls.org/lls-us-hq/news/the-leukemia-lymphoma-society-launches-groundbreaking-precision-medicine-approach-to-treat-acute-myeloid-leukemia-one-of-the-deadliest-blood-cancers

"Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.

Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.

AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.

With support and guidance from the U.S. Food and Drug Administration (FDA), and LLS as the sponsor, the ambitious Beat AML Master Trial seeks to change the paradigm for how this deadly cancer is treated, using an innovative precision medicine protocol. This approach will employ comprehensive genomic profiling (CGP) to find and match specific AML genetic mutations in newly diagnosed patients over age 60, with an investigational drug or drug combination potentially best suited to attack the specific molecular mutations causing the cancer.

According to Louis J. DeGennaro, Ph.D., LLS President and CEO, “The Leukemia & Lymphoma Society is uniquely qualified to lead this unprecedented clinical trial collaboration, rare for a non-profit and a first for LLS. Beat AML, as we have named this Master Trial, showcases LLS’s stature in the cancer ecosystem,” he explained. “It demonstrates our ability to convene the medical and research communities to think and act boldly in the quest for new and better treatments for blood cancer patients, and our aim to accelerate the rate at which precisely targeted breakthrough therapies reach the patients who urgently need them.”

..."
Posted by slipslidingaway | Thu Oct 20, 2016, 11:14 PM (6 replies)
Go to Page: 1